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and Shiwei Duan1*Abstract
Objective: Colorectal cancer (CRC) is one of the most common digestive malignancies in the world. EDNRB is a new
candidate tumor suppressor gene which is often down-regulated or even silenced by promoter hypermethylation in
various human cancers. However, the function of EDNRB gene in CRC remains unknown. In this study, we examined
the expression and DNA methylation of EDNRB in CRC tissues.
Methods: A total of 42 paired CRC and adjacent normal tissue samples were used to determine mRNA levels and DNA
methylation status of EDNRB gene by qRT-PCR and methylation-specific PCR (MSP), respectively.
Results: Our study showed that EDNRB promoter hypermethylation was more frequently in CRC tissues than in the
normal tissues (92.86 versus 59.52, p = 0.001). Consequently, significantly lower level of EDNRB mRNA was found in CRC
tumor samples than in normal samples (0.31 ± 0.91 versus 0.70 ± 1.18, p = 0.032).
Conclusions: Our results suggested that EDNRB promoter hypermethylation might downregulate its gene expression
in CRC, and thus played an important role in the development of CRC.
The virtual slide: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
7420980471113303
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Colorectal cancer (CRC) is a malignant disease caused
by a variety of factors involving with the accumulation
of genetic and epigenetic changes. The incidence of CRC
is increasing rapidly, and there are 1 million new CRC
cases annually [1]. In the developed countries, the mor-
tality of CRC has soared up to 33. CRC has become the
second most common cancer in the world [2], account-
ing for 9 of all malignant tumors deaths [3]. Although 5-
year survival rate of CRC patients has been improved
from 22 to 47 in the last 30 years due to the advance-
ment of the early diagnosis, surgical techniques and
adjuvant therapies, the overall survival rate remains
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stated.Abberrant expression of some important genes, such
as beta-catenin [4], SATB1 [5] and EGFR [6], were
shown to be significantly associated with the occurrence
and prognosis of CRC. Gene promoter hypermethylation
often silences gene expression, while promoter hypome-
thylation tends to activate gene transcription. DNA
methylation alteration has been considered as an im-
portant event in many malignancies including CRC.
Endothelin receptor type B (EDNRB) gene is located
on 13q22, encoding a nonselective endothelin B receptor
(ETBR) which belongs to a super-family of G-protein
coupled receptor that mediates endothelins (ETs) [7].
ETBR is able to promote the production of neural crest
cell-specific lineage, and thus it is related to the occur-
rence of Hirschsprung’s disease [8] that is a blockage in
the colon.
There are massive CpG dinucleotide repeats in the 5′-
flanking region of EDNRB gene. The methylation of this
CpG-riched region was shown to be able to regulate
EDNRB gene expression [9-11]. Hypermethylation oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Table 1 List of all primers used and conditions of PCR
amplification
Primer Sequence (5′-3′) Product
size (bp)
M F CGAAGAGGTTGCGGGCGGTATTAGCG 130
R TACTCCAAAAACGTCCGATAACCG
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[12], oral cancer [13], skin cancer [14], head and neck
cancer [15], melanoma [16], renal cell carcinoma [17],
bladder cancer [18] and prostate cancer [19]. However,
the function of EDNRB gene in CRC remains unknown.
In light of previous findings in various cancers, we inves-
tigate whether EDNRB gene promoter methylation con-
tributes to the risk of CRC in Chinese population.
Materials and methods
Tissue samples collection
Tumor and its normal adjacent tissue samples were col-
lected at the time of surgery from 42 primary sporadic
CRC patients in the Department of Gastrointestinal Sur-
gery in Affiliated Hospital of Ningbo University between
June 2012 and April 2013. Normal adjacent tissues were
collected at least 5 cm away from the tumor. Tissues
were stored in liquid nitrogen at −80°C immediately
after excision. The diagnoses of all CRC cases were
pathologically confirmed. None of CRC patients had re-
ceived preoperative chemotherapy or radiation therapy.
Tumor stage was determined according to the Duke’s
staging system, and cellular differentiation was graded
according to the Broders’ grading system. All the pa-
tients in the study have signed the informed written con-
sent forms.
DNA isolation
Genomic DNA from tissue samples were extracted with
QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) ac-
cording to the manufacturer’s instruction. Briefly, tissue
sections were incubated with 180 μl of buffer ATL (in
QIAamp DNA Mini Kit) and 20 μl of proteinase K on a
thermostatic water bath at 56°C for 3 h, followed by in-
cubation at 70°C for 10 min. Then, 200 μl of remixed
Buffer AL (in QIAamp DNA Mini Kit) and ethanol
(ratio 1:1) were added. Samples were mixed and trans-
ferred into QIAamp Mini spin columns. Centrifugation
at 8,000 rpm for 1 min was followed by washing the spin
column membrane with 500 μl of Buffer AW1 and
500 μl of Buffer AW2. DNA was eluted with 100 μl of
Buffer AE. DNA concentration and quality were deter-
mined with spectrophotometer.
Bisulfite modification
Eluted DNA was bisulphite-treated with ZYMO EZ
DNA Methylation-Gold Kit according to the manufac-
turer’s instruction (Zymo Research, Orange, CA, USA).
The bisulphite-modified DNA was resuspended in 10 μl
of TE buffer.
Methylation-specific PCR (MSP)
Methylation status of EDNRB promoter was determined
by MSP. For the PCR reaction, 2 μl of modified DNAwas amplified in a 20 μl reaction containing 0.3 μM each
of forward and reverse primers, 0.2 mM dNTPs, 10 ×
PCR Buffer and 2.5 U of Hot Start DNA Polymerase
(Qiagen, Hilden, Germany) under the following condi-
tions: 15 min of denaturation at 95°C followed by 35 cy-
cles of 45 s at 94°C, 45 s at 62°C for methylated primers,
1 min at 72°C and a final extension for 10 min at 72°C.
The sequences of methylated and unmethylated primers
were given in the previous study [20] (Table 1). Water
blank was used as a negative control. PCR products were
subjected to 2.0 agarose gel electrophoresis at 100 V for
20 min, and visualized directly under UV illumination.
Samples were considered as methylation or unmethyla-
tion, when there were clearly visible bands (130 or
134 bp) on the gel for methylation or unmethylation
primers.
RNA isolation and reverse transcription
Total RNA was extracted from fresh frozen CRC and nor-
mal tissues from the same patients. RNA was extracted
with TRIZOL reagent (Invitrogen Life Technologies Co,
USA) according to the manufacturer’s protocol. RNA
concentration and quality were determined by Nano-
Drop ND-1000 (Thermal Fisher Scientific, USA). The
first-strand cDNA was synthesized according to the
manufacturer’s instruction of M-MLV Reverse Tran-
scriptase (Promega, Wisconsin, USA) with 2 μg DNase
I-treated total RNA and 2 μM Oligo (dT)15 primer in a
20 μL volume.
qRT-PCR
Primers for qRT-PCR were listed in Table 1 [21]. The
qRT-PCR reactions were conducted in a 96-well plate
using ABI7500 Real-Time system (Applied Biosystems,
CA, USA). Each reaction was performed in triplicate
and in a 20 μL volume containing 2× real-time PCR
Master Mix with SYBR Green dye (Promega, Wisconsin,
USA), 0.4 μM of each primer and 4 μL cDNA, using the
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by 40 cycles of 95°C for 15 s, 60°C for 1 min and 72°C
for 40 s. A melting curve analysis from 60°C to 95°C was
performed at the end of each PCR to further confirm
the specificity of amplicons. GAPDH was used as an en-
dogenous control. The Ct values displayed by the instru-
ment were recorded. Samples were confirmed whether
there was a clearly visible band (86/194 bp) on the gel
with EDNRB or GAPDH primers (Figure 1).
Statistics
Statistical analysis was performed by the SPSS statistical
package (version 16.0; SPSS, Chicago, IL, USA) and the
results were presented using GraphPad prism software.
Comparisons of EDNRB promoter methylation were
performed by the correction formula of Chi-square test.
The 2–ΔCt method was used to analyze the result of
qRT-PCR. Two groups of related data were analyzed
using paired t-test. The Mann-Whiteney U test was used
for two groups of independent data which did not meetFigure 1 EDNRB and GAPDH mRNA expression in CRC
tumor tissue.normality test. All analyses were two-sided, and p < 0.05
was considered statistically significant.
Results
Hypermethylated EDNRB promoter in CRC
To determine methylation of EDNRB gene, MSP was per-
formed on 42 CRC and 42 adjacent normal tissues in the
primary sporadic CRC patients. The representative agar-
ose gel electrophoresis results were shown in Figure 2.
Methylation status was determined when there were
methylated bands in the gel. And unmethylation status
was determined if both the methylated and unmethylated
bands were not detected, For the unmethylated samples,
we repeated the relative experiment two times, including
testing the DNA quality, bisulphite modification and MSP
(confirming PCR primers quality and PCR conditions). If
the methylated and unmethylated bands still did not de-
tect, we confirmed the status of the sample as unmethyla-
tion. Our study showed that hypermethylation of EDNRB
in CRC tissues was more frequently than in corresponding
normal tissues (92.86 versus 59.52, p = 0.001, Table 2).
Correlation of EDNRB methylation with clinicopathological
characteristics
The relationship between methylation status of EDNRB
gene and the clinicopathological characteristics of CRC
was shown in Table 3. There was no significant differ-
ence in clinicopathological factors such as gender, age,
TNM stages, lymph node status, metastasis status,
tumor location, differentiation status, tumor size, and
histological grade. There was no correlation of EDNRB
gene methylation status with the serum levels of carci-
noembryonic antigen (CEA) and carbohydrate antigen
19–9 (CA19-9).
EDNRB expression is down-regulated in CRC tissues
We determined EDNRB mRNA expression in 42 CRC
tissues and 42 adjacent normal colorectal tissues by
qRT-PCR. The gene expression level of EDNRB was
normalized with the values of the control gene GAPDH.
Our results showed that EDNRB mRNA level in CRC
tumor samples was significantly lower than in their adjacent
normal samples (0.31 ± 0.91 versus 0.70 ± 1.18, p = 0.032,
Figure 3, Table 4).
Correlation of EDNRB expression status with
clinicopathological characteristics
We further examined the relationship between EDNRB
mRNA expression and clinicopathological characteristics
(Table 5). There was no significant correlation between
EDNRB expression and the clinicopathological factors
such as gender, age, TNM stages, lymph node status,
metastasis status, tumor location, differentiation status,
tumor size, and histological classification.
Figure 2 Representative results for methylation status of EDNRB gene in CRC tumor tissues (T) and adjacent normal tissues (N).
Table 3 Association between the EDNRB methylation in
CRC serum and clinicopathologicalfeatures
EDNRB
Methylation
Characteristics n M U χ2 p value
Gender Male 28 27 1 0.404 0.525
Female 14 12 2
Age(year) ≤60 16 16 0 0.629 0.428
>60 26 23 3
Stage 1/2 21 18 3 1.436 0.231
3/4 21 21 0
Lymph
metastasis
Yes 21 21 0 1.436 0.231
No 21 18 3
Distant
metastasis
Yes 8 8 0 0.012 0.913
No 34 31 3
CEA ≥5.0 ng/ml 15 14 1 <0.001 1
<5.0 ng/ml 27 25 2
CA19-9 ≥37U/ml 9 8 1 <0.001 1
<37U/ml 33 31 2
Tumor location Colon 26 24 2 <0.001 1
Rectum 16 15 1
Differentiation Poor 10 10 0 0.091 0.763
Moderate 32 29 3
Well 0 0 0
Tumor size <5 cm 28 25 3 0.404 0.525
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Cancer development and progression may be contrib-
uted by both genetic and epigenetic factors. As one of
the major epigenetic modifications, DNA methylation of
promoter often down-regulates gene transcription. A
growing number of evidences show that DNA methyla-
tion mediated tumor suppressor gene silencing may con-
tribute to tumor progression [22-24]. Aberrant DNA
methylated loci have become promising biomarkers in
the early diagnosis of diseases [25,26].
EDNRB is a G protein–coupled receptor that activates a
phosphatidylinositol-calcium second messenger system. The
product of EDNRB gene (ETB receptor, ETBR) is able to
bind to endothelins (ETs), consisting of a family of 3 potent
vasoactive peptides (ET1, ET2, and ET3) [13]. During the
development of tumor, EDNRB gene transcription is down-
regulated by promoter hypermethylated, and consequently
alters the ET1 signaling pathway [27]. Disruption in the
ET1 signaling pathway has been shown to be involved
in a variety of human tumor proliferation, angiogenesis,
and metastasis [28-30]. EDNRB gene silencing by pro-
moter hypermethylation has been reported in a variety
of tumors such as leukemia, oral cancer, skin cancer,
head and neck cancer, melanoma, renal cell carcinoma,
bladder cancer, and prostate cancer [12-19]. Our study
in CRC adds a new piece of evidence for the contribu-
tion of EDNRB promoter hypermethylation to the risk
of CRC. Our results further confirmed that DNA
methylation in the promoter region played a key role in
EDNRB transcription.
Some reports have focused on the correlation between
EDNRB methylation and cancer clinical features [31-33].
Hypermethylation of the EDNRB gene in paired gastricTable 2 Methylation status of EDNRB gene in CRC and
normal tissues
Total M U M% χ2 p value
CRC cases 42 39 3 92.86 11.091 0.001
Controls 42 25 17 59.52
≥5 cm 14 14 0
Histological
classification







Table 5 Correlation of EDNRB mRNA expression and




Characteristics n Mean SD SE p value
Gender Male 28 0.336 1.073 0.202 0.722
Female 14 0.250 0.480 0.130
Age (year) ≤60 16 0.221 0.444 0.111 0.836
>60 26 0.360 1.114 0.218
Stage 1/2 21 0.143 0.233 0.051 0.792
3/4 21 0.472 1.257 0.281
Lymph
metastasis
Yes 21 0.457 1.266 0.276 0.95
No 21 0.158 0.238 0.052
Distant
metastasis
Yes 8 0.781 1.996 0.706 0.741
No 34 0.196 0.351 0.060
CEA ≥5.0 ng/ml 15 0.121 0.156 0.040 0.723
<5.0 ng/ml 27 0.411 1.127 0.217
CA19-9 ≥37U/ml 9 0.102 0.153 0.051 0.526
<37U/ml 33 0.364 1.023 0.178
Tumor location Colon 26 0.428 1.145 0.225 0.351
Rectum 16 0.112 0.156 0.039
Differentiation Poor 10 0.719 1.779 0.558 0.494
Moderate 32 0.179 0.341 0.062
Well 0 / / /
Tumor size <5 cm 28 0.386 1.102 0.208 0.968
≥5 cm 14 0.151 0.248 0.066
Histological
classification
Adenocarcinoma 40 0.315 0.935 0.148 0.455
Mucinous
adenocarcinoma
2 0.162 0.157 0.111
Undifferentiated
carcinoma
0 / / /
*: SD denotes standard deviation and SE denotes standard error.
Figure 3 Expression level of EDNRB gene in CRC tumor tissues
(T) and adjacent normal tissues (N). RT-qPCR was used to analyze
the expression level of EDNRB gene in CRC tumor tissues and adjacent
normal tissues. The relative expression of EDNRB mRNA level was
significantly higher in normal tissues than that in CRC tumor
tissues (p = 0.032).
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tients was detected [32]. EDNRB gene promoter methy-
lation was shown to be associated with gastric cancer
tumor invasion [32]. The extent of hypermethylation at
CpG island in EDNRB gene was also evaluated in seven
prostate cancer cell lines, normal prostate epithelial cells,
normal prostate stromal cells, 73 primary prostate can-
cers, 91 metastatic prostate cancers, and 25 noncancerous
prostate tissues [33]. EDNRB CpG island hypermethyla-
tion was shown to be correlated with pathological stage
and Gleason score to a statistically significant extent in
prostate cancer [33]. In the present study, we examined
the relationship between the EDNRB methylation and the
clinical features. Unfortunately, there was no significant
relationship between EDNRB methylation or expression
status and the clinical features. And this may be due to a
lack of power in our samples. As a kind of glycoprotein
produced by colorectal cancer tissue, CEA is a good
tumor marker for judging efficacy, disease progression,
and prognosis of colorectal cancer. CA19-9 was frequently
increased in gastrointestinal tumors such as pancreatic
cancer, gastric cancer, and colorectal cancer. CEA and
CA19-9 are commonly and traditionally used in clinical
colorectal cancer detection. Our study showed no correl-
ation of EDNRB gene methylation status with the serumTable 4 EDNRB mRNA expression levels in CRC and
normal tissues*
Total Mean SD SE t p value
CRC 42 0.3074 0.91 0.14 −2.214 0.032
Control 42 0.7041 1.18 0.18
*: SD denotes standard deviation and SE denotes standard error.levels of CEA and CA19-9. This might imply that aberrant
EDNRB methylation and conventional tumor markers
could serve as complementary markers in the CRC diag-
nosis, although further work is needed to confirm our
hypothesis.
In conclusion, we revealed a significant contribution of
EDNRB hypermethylation to the risk of CRC. These find-
ings may provide a new clue for detection and treatment
of CRC. Future research is needed to determine the de-
tailed mechanism of EDNRB gene in the risk of CRC.Abbreviations
CRC: Colorectal cancer; EDNRB: Endothelin receptor type B; ETAR: Endothelin
A receptor; ETBR: Endothelin B receptor; ETs: Endothelins.
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